M&G Investment Management Ltd. Has $3.40 Million Position in HUTCHMED (China) Limited (NASDAQ:HCM)

M&G Investment Management Ltd. trimmed its stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 97.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 188,669 shares of the company's stock after selling 6,896,165 shares during the period. M&G Investment Management Ltd. owned 0.11% of HUTCHMED worth $3,396,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new position in shares of HUTCHMED in the 3rd quarter worth $3,268,000. China Universal Asset Management Co. Ltd. grew its position in HUTCHMED by 353.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,593 shares of the company's stock worth $65,000 after acquiring an additional 2,801 shares in the last quarter. Baillie Gifford & Co. increased its stake in HUTCHMED by 7.2% during the fourth quarter. Baillie Gifford & Co. now owns 144,969 shares of the company's stock worth $2,625,000 after acquiring an additional 9,694 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in HUTCHMED during the third quarter valued at approximately $444,000. Finally, Hsbc Holdings PLC bought a new stake in shares of HUTCHMED in the 3rd quarter valued at approximately $380,000. 8.82% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, StockNews.com downgraded HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $29.70.

HUTCHMED Trading Down 2.7 %

Shares of NASDAQ HCM traded down $0.59 during trading on Thursday, hitting $20.96. The company had a trading volume of 116,658 shares, compared to its average volume of 126,847. The stock has a fifty day simple moving average of $17.80 and a two-hundred day simple moving average of $17.02. The company has a quick ratio of 2.60, a current ratio of 2.72 and a debt-to-equity ratio of 0.06. HUTCHMED has a fifty-two week low of $10.68 and a fifty-two week high of $21.92.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.